Detalhe da pesquisa
1.
A randomised placebo-controlled, double-blind phase II study to explore the safety, efficacy, and pharmacokinetics of sonlicromanol in children with genetically confirmed mitochondrial disease and motor symptoms ("KHENERGYC").
BMC Neurol
; 22(1): 158, 2022 Apr 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-35477351
2.
The use of mono- and combination drug therapy in men and women with lower urinary tract symptoms (LUTS) in the UK: a retrospective observational study.
BMC Urol
; 21(1): 119, 2021 Sep 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34474675
3.
Safety and Efficacy of Fidaxomicin and Vancomycin in Children and Adolescents with Clostridioides (Clostridium) difficile Infection: A Phase 3, Multicenter, Randomized, Single-blind Clinical Trial (SUNSHINE).
Clin Infect Dis
; 71(10): 2581-2588, 2020 12 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-31773143
4.
Long-term treatment of older patients with overactive bladder using a combination of mirabegron and solifenacin: a prespecified analysis from the randomized, phase III SYNERGY II study.
Neurourol Urodyn
; 38(2): 779-792, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30644570
5.
Patient-reported outcomes from SYNERGY, a randomized, double-blind, multicenter study evaluating combinations of mirabegron and solifenacin compared with monotherapy and placebo in OAB patients.
Neurourol Urodyn
; 37(1): 394-406, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28704584
6.
Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study).
BJU Int
; 120(4): 562-575, 2017 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28418102
7.
Electronic bladder diaries of differing duration versus a paper diary for data collection in overactive bladder.
Neurourol Urodyn
; 35(6): 743-9, 2016 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-26174907
8.
Efficacy of oral 20-hydroxyecdysone (BIO101), a MAS receptor activator, in adults with severe COVID-19 (COVA): a randomized, placebo-controlled, phase 2/3 trial.
EClinicalMedicine
; 68: 102383, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38545090
9.
Novel Potential Targets for Function-Promoting Therapies: Orphan Nuclear Receptors, Anti-inflammatory Drugs, Troponin Activators, Mas Receptor Agonists, and Urolithin A.
J Gerontol A Biol Sci Med Sci
; 78(Suppl 1): 44-52, 2023 06 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-37325960
10.
Community Consensus Guidelines to Support FAIR Data Standards in Clinical Research Studies in Primary Mitochondrial Disease.
Adv Genet (Hoboken)
; 3(1)2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-35317023
11.
Long-term Safety and Efficacy of Mirabegron and Solifenacin in Combination Compared with Monotherapy in Patients with Overactive Bladder: A Randomised, Multicentre Phase 3 Study (SYNERGY II).
Eur Urol
; 74(4): 501-509, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-29866467
12.
Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony).
Eur Urol
; 67(3): 577-88, 2015 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-24612659